Cargando…
Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer
Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leuk...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664263/ https://www.ncbi.nlm.nih.gov/pubmed/34890222 http://dx.doi.org/10.1126/sciadv.abk3521 |
_version_ | 1784613810692161536 |
---|---|
author | Soukup, Alexandra A. Matson, Daniel R. Liu, Peng Johnson, Kirby D. Bresnick, Emery H. |
author_facet | Soukup, Alexandra A. Matson, Daniel R. Liu, Peng Johnson, Kirby D. Bresnick, Emery H. |
author_sort | Soukup, Alexandra A. |
collection | PubMed |
description | Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe “conditionally pathogenic” (CP) enhancer motif variants that differentially affect hematopoietic development and regeneration. The Ets motif variant functioned autonomously in hematopoietic cells to disrupt hematopoiesis. Because an epigenetically silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics. |
format | Online Article Text |
id | pubmed-8664263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-86642632021-12-16 Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer Soukup, Alexandra A. Matson, Daniel R. Liu, Peng Johnson, Kirby D. Bresnick, Emery H. Sci Adv Biomedicine and Life Sciences Human genetic variants are classified on the basis of potential pathogenicity to guide clinical decisions. However, mechanistic uncertainties often preclude definitive categorization. Germline coding and enhancer variants within the hematopoietic regulator GATA2 create a bone marrow failure and leukemia predisposition. The conserved murine enhancer promotes hematopoietic stem cell (HSC) genesis, and a single-nucleotide human variant in an Ets motif attenuates chemotherapy-induced hematopoietic regeneration. We describe “conditionally pathogenic” (CP) enhancer motif variants that differentially affect hematopoietic development and regeneration. The Ets motif variant functioned autonomously in hematopoietic cells to disrupt hematopoiesis. Because an epigenetically silenced normal allele can exacerbate phenotypes of a pathogenic heterozygous variant, we engineered a bone marrow failure model harboring the Ets motif variant and a severe enhancer mutation on the second allele. Despite normal developmental hematopoiesis, regeneration in response to chemotherapy, inflammation, and a therapeutic HSC mobilizer was compromised. The CP paradigm informs mechanisms underlying phenotypic plasticity and clinical genetics. American Association for the Advancement of Science 2021-12-10 /pmc/articles/PMC8664263/ /pubmed/34890222 http://dx.doi.org/10.1126/sciadv.abk3521 Text en Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Soukup, Alexandra A. Matson, Daniel R. Liu, Peng Johnson, Kirby D. Bresnick, Emery H. Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title | Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title_full | Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title_fullStr | Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title_full_unstemmed | Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title_short | Conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
title_sort | conditionally pathogenic genetic variants of a hematopoietic disease–suppressing enhancer |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664263/ https://www.ncbi.nlm.nih.gov/pubmed/34890222 http://dx.doi.org/10.1126/sciadv.abk3521 |
work_keys_str_mv | AT soukupalexandraa conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer AT matsondanielr conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer AT liupeng conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer AT johnsonkirbyd conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer AT bresnickemeryh conditionallypathogenicgeneticvariantsofahematopoieticdiseasesuppressingenhancer |